SEARCH

SEARCH BY CITATION

References

  • 1
    Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 5967.
  • 2
    Emery DJ, Diaz LA, Fairley JA et al. Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. J Invest Dermatol 1995; 104: 3238.
  • 3
    Harman KE, Gratian MJ, Bhogal BS et al. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol 2000; 143: 3438.
  • 4
    Ding X, Aoki V, Mascaro JM Jr et al. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109: 5926.
  • 5
    Amagai M, Tsunoda K, Zillikens D et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 16770.
  • 6
    Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 20312.
  • 7
    Wolf R, Landau M, Tur E, Brenner S. Early treatment of pemphigus does not improve the prognosis. A review of 53 patients. J Eur Acad Dermatol Venereol 1995; 4: 1316.
  • 8
    Mourellou O, Chaidemenos GC, Koussidou TH, Kapetis E. The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol 1995; 133: 837.
  • 9
    Bhogal BS, Black MM. Diagnosis, diagnostic and research techniques. In: Management of Blistering Diseases (WojnarowskaF, BriggamanRA, eds). London: Chapman & Hall, 1990; 1534.
  • 10
    Bhogal BS, Wojnarowska F, Black MM et al. The distribution of immunoglobulins and the C3 component of complement in multiple biopsies from the uninvolved and perilesional skin in pemphigus. Clin Exp Dermatol 1986; 11: 4953.
  • 11
    Judd KP, Lever WF. Correlation of antibodies in skin and serum with disease severity in pemphigus. Arch Dermatol 1979; 115: 42832.
  • 12
    Lever WF. Pemphigus and pemphigoid. A review of the advances made since 1964. J Am Acad Dermatol 1979; 1: 231.
  • 13
    Amagai M, Komai A, Hashimoto T et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999; 140: 3517.
  • 14
    Harman KE, Gratian MJ, Seed PT et al. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 1999; 25: 23640.
  • 15
    Chryssomallis F, Ioannides D, Teknetzis A et al. Treatment for oral pemphigus. Int J Dermatol 1994; 33: 8037.
  • 16
    Scully C, Paes de Almeida O, Porter SR, Gilkes JJH. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 1999; 140: 849.
  • 17
    Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42: 4227.
  • 18
    Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporin as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136: 86872.
  • 19
    Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996; 34: 64552.
  • 20
    Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 1984; 120: 447.
  • 21
    Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. Int J Dermatol 1990; 29: 3637.
  • 22
    Lapidoth M, David M, Ben-Amitai D et al. The efficacy of combined treatment with prednisolone and cyclosporin in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994; 30: 7527.
  • 23
    Lever WF, White H. Treatment of pemphigus with corticosteroids. Results obtained in 46 patients over a period of 11 years. Arch Dermatol 1963; 87: 1225.
  • 24
    Katz SI, Halprin KM, Inderbitzin TM. The use of human skin for the detection of anti-epithelial autoantibodies. J Invest Dermatol 1969; 53: 3909.
  • 25
    Rosenberg FR, Sanders S, Nelson CT. Pemphigus. A 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 96270.
  • 26
    Hirone T. Pemphigus: a survey of 85 patients between 1970 and 1974. J Dermatol 1978; 5: 437.
  • 27
    Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996; 132: 14359.
  • 28
    Chryssomallis F, Dimitriades A, Chaidemenos GC et al. Steroid-pulse therapy in pemphigus vulgaris long term follow-up. Int J Dermatol 1995; 34: 43842.
  • 29
    Wolff K, Schreiner E. Immunosuppressive Therapie bei Pemphigus vulgaris. Arch Klin Exp Dermatol 1969; 235: 6377.
  • 30
    Van Dijk TJA, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica 1973; 147: 17985.
  • 31
    Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol 1987; 16: 52733.
  • 32
    Krakowski A, Covo J, Rozanski Z. Pemphigus vulgaris. Arch Dermatol 1969; 100: 117.
  • 33
    Burton JL, Greaves MW, Marks J, Dawber RPR. Azathioprine in pemphigus vulgaris. Br Med J 1970; 3: 846.
  • 34
    Roenigk HH, Deodhar S. Pemphigus treatment with azathioprine. Arch Dermatol 1973; 107: 3537.
  • 35
    Holme SA, Duley J, Anstey AV. Thiopurine methyltransferase screening prior to azathioprine treatment in the United Kingdom. Br J Dermatol 2001; 145 (Suppl. 59): 12(Abstr.)
  • 36
    Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 1937.
  • 37
    Anstey A. Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995; 88: 15560.
  • 38
    Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus. J Am Acad Dermatol 1999; 135: 8534.
  • 39
    Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1972; 106: 65761.
  • 40
    Fellner MJ, Katz JM, McCabe JB. Successful treatment of cyclophosphamide and prednisolone for initial treatment of pemphigus vulgaris. Arch Dermatol 1978; 114: 88994.
  • 41
    Pasricha JS, Sood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. Br J Dermatol 1975; 93: 5736.
  • 42
    Piamphongsant T. Treatment of pemphigus with corticosteroids and cyclophosphamide. J Dermatol 1979; 6: 35963.
  • 43
    Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol 1987; 17: 43742.
  • 44
    Pasricha JS, Ramji G. Pulse therapy with dexamethasone–cyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol 1984; 50: 199203.
  • 45
    Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone–cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34: 87582.
  • 46
    Pasricha JS, Khaitan BK. Curative treatment for pemphigus. Arch Dermatol 1996; 132: 151819.
  • 47
    Kumrah L, Ramam M, Shah P et al. Pituitary–adrenal function following dexamethosone–cyclophosphamide pulse therapy for pemphigus. Br J Dermatol 2001; 145: 9448.
  • 48
    Kaur S, Kanwar AJ. Dexamethasone–cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990; 29: 3714.
  • 49
    Enk AH, Knop J. Mycophenolate mofetil is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 546.
  • 50
    Nousari HC, Sragovich A, Kimyai-Asadi A et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 2658.
  • 51
    Bredlich RO, Grundmann-Kollmann M, Behrens S et al. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol 1999; 141: 934 (Letter).
  • 52
    Grundmann-Kollmann M, Kaskel P, Leiter U et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999; 135: 7245.
  • 53
    Penneys NS, Eaglstein WH, Indgin S, Frost P. Gold sodium thiomalate treatment of pemphigus. Arch Dermatol 1973; 108: 5660.
  • 54
    Sutej PG, Jorizzo JL, White W. Intramuscular gold therapy for young patients with pemphigus vulgaris: a prospective, open, clinical study utilising a dermatologist/rheumatologist team approach. J Eur Acad Dermatol Venereol 1995; 5: 2228.
  • 55
    Penneys NS, Eaglstein WH, Frost P. Management of pemphigus with gold compounds. A long-term follow-up report. Arch Dermatol 1976; 112: 1857.
  • 56
    Pandya AG, Dyke C. Treatment of pemphigus with gold. Arch Dermatol 1998; 134: 11047.
  • 57
    Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol 1969; 100: 708.
  • 58
    Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol 1970; 83: 31523.
  • 59
    Ryan JG. Pemphigus. A 20-year survey of experience with 70 cases. Arch Dermatol 1971; 104: 1420.
  • 60
    Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol 1972; 106: 4917.
  • 61
    Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999; 135: 12756.
  • 62
    Barthelemy H, Frappaz A, Cambazard F et al. Treatment of nine cases of pemphigus vulgaris with cyclosporin. J Am Acad Dermatol 1988; 18: 12626.
  • 63
    Alijotas J, Pedragosa R, Bosch J, Vilardell M. Prolonged remission after cyclosporin therapy in pemphigus vulgaris: report of two young siblings. J Am Acad Dermatol 1990; 23: 7013.
  • 64
    Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 1993; 28: 9981000.
  • 65
    Alpsoy E, Yilmaz E, Basaran E et al. Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus? Arch Dermatol 1995; 131: 133940.
  • 66
    Calebotta A, Saenz AM, Gonzalez F et al. Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol 1999; 38: 21721.
  • 67
    Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol 1996; 37: 935.
  • 68
    Ozog DM, Gogstetter DS, Scott G, Gaspari AA. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol 2000; 136: 11338.
  • 69
    Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol 1976; 94: 6816.
  • 70
    Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978; 156: 1203.
  • 71
    Bjarnason B, Skoglund C, Flosadottir E. Childhood pemphigus vulgaris treated with dapsone: a case report. Pediatr Dermatol 1998; 15: 3813.
  • 72
    Shah N, Green AR, Elgart GW, Kerdel F. The use of chlorambucil with prednisolone in the treatment of pemphigus. J Am Acad Dermatol 2000; 42: 858.
  • 73
    Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989; 20: 6845.
  • 74
    Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous gamma-globulin in pemphigus. J Am Acad Dermatol 1990; 22: 326.
  • 75
    Messer G, Sizmann N, Feucht H, Meurer M. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 1995; 133: 101018.
  • 76
    Beckers RCY, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 28993.
  • 77
    Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 1996; 135: 1289.
  • 78
    Wever S, Zillikens D, Brocker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 1996; 135: 8623.
  • 79
    Colonna L, Cianchini G, Frezzolini A. Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy. Br J Dermatol 1998; 138: 11023.
  • 80
    Jolles S, Hughes J, Rustin M. Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris. J Am Acad Dermatol 1999; 40: 499500.
  • 81
    Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 86574.
  • 82
    Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 67990.
  • 83
    Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47: 35863.
  • 84
    Guillaume JC, Roujeau JC, Morel P et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988; 124: 165963.
  • 85
    Ruocco V, Rossi A, Argenziano G et al. Pathogenicity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis. Br J Dermatol 1978; 98: 23741.
  • 86
    Cotterill JA, Barker DJ, Millard LG, Robinson EA. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978; 98: 243.
  • 87
    Meurer M, Braun-Falco O. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1979; 100: 2312.
  • 88
    Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol 1979; 115: 72830.
  • 89
    Swanson DL, Dahl MV. Pemphigus vulgaris and plasma exchange: clinical and serologic studies. J Am Acad Dermatol 1981; 4: 3258.
  • 90
    Roujeau JC, Kalis B, Lauret P et al. Plasma exchange in corticosteroid-resistant pemphigus. Br J Dermatol 1982; 106: 1034.
  • 91
    Roujeau JC, Andre C, Joneau Fabre M et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol 1983; 119: 21521.
  • 92
    Ruocco V, Astarita C, Pisani M. Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica 1984; 168: 21923.
  • 93
    Euler HN, Loeffler H, Christophers E. Synchronisation of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. Arch Dermatol 1987; 123: 120510.
  • 94
    Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22: 3540.
  • 95
    Sondergaard K, Carstens J, Jorgensen J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus. Acta Derm Venereol (Stockh)1995; 75: 1502.
  • 96
    Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 105864.
  • 97
    Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol 1988; 124: 17024.
  • 98
    Blaszczyk M, Chorzelski TP, Jablonska S et al. Indications for future studies on the treatment of pemphigus with plasmapheresis. Arch Dermatol 1989; 125: 8434 (Letter).
  • 99
    Roujeau JC. Plasmapheresis therapy of pemphigus and bullous pemphigoid. Semin Dermatol 1988; 7: 195200.
  • 100
    Ruocco V. Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or reappraisal? Arch Dermatol 1988; 124: 171618.
  • 101
    Rook AH, Jegasothy BV, Heald P et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 1990; 112: 3035.
  • 102
    Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992; 26: 77980.
  • 103
    Gollnick HPM, Owsianowski M, Taube KM, Orfanos CE. Unresponsive severe generalised pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol 1993; 28: 1224.
  • 104
    Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology 1999; 198: 1404.
  • 105
    Huilgol SC, Black MM. Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 1995; 20: 28393.
  • 106
    Huilgol SC, Black MM. Management of the immunobullous disorders. I. Pemphigoid. Clin Exp Dermatol 1995; 20: 189201.
  • 107
    Eisen D, Ellis CN. Topical cyclosporin for oral mucosal disorders. J Am Acad Dermatol 1990; 23: 125964.
  • 108
    Goopta C, Staughton RCD. Use of topical cyclosporin in oral pemphigus. J Am Acad Dermatol 1998; 38: 8601.
  • 109
    David M, Weissman-Katzenelson V, Ben-Chetrit A et al. The usefulness of immunofluorescent tests in pemphigus patients in clinical remission. Br J Dermatol 1989; 120: 3915.
  • 110
    Ratnam KV, Pang BK. Pemphigus in remission: value of negative direct immunofluorescence in management. J Am Acad Dermatol 1994; 30: 54750.
  • 111
    Griffiths CEM.. The British Association of Dermatologists guidelines for the management of skin disease.Br J Dermatol 1999; 141: 3967.
  • 112
    Cox NH. Williams HC. The British Association of Dermatologists therapeutic guidelines: can we AGREE?Br J Dermatol 2003; 148: 6215.